Psoriasis Drugs Market Size Is Projected to Reach USD 13.1 Billion at a CAGR of 7.3% By 2025

“Psoriasis Drugs Market”

Psoriasis Drugs Market Size, Growth and Share Analysis By Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α) Inhibitors, InterleU.K.in 12 and 23 (IL-12/23) Inhibitors, Interleukin 17 (IL-17) Inhibitor, T cell Inhibitor]}, Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2025

Psoriasis Drugs Market Analysis

The Psoriasis Drugs Market is predicted to touch USD 13.1 billion at a 7.3% CAGR between 2019-2025, states the latest Market Research Future (MRFR) report. Psoriasis, simply put, is an autoimmune condition that causes rapid development of cells on the skin. The overgrowth can result in scaly, thick plaques that may itch and cause discomfort. Scales generally develop on joints, especially the knees and elbows, but it may appear in any part of the body including the face, scalp, neck, feet, and hands. 

Various factors are propelling the global Psoriasis Drugs Market growth. Such factors, according to the latest Market Research Future report, include vulnerability towards psoriatic arthritis, favorable reimbursement policies, growing awareness about psoriasis, increasing availability of biosimilars and biologics, aging population and changing lifestyle. Additional factors propelling the growth of the Psoriasis Drugs Market include rising prevalence of autoimmune diseases, increasing incidence of psoriasis, increasing R&D activities for psoriasis treatment, and technological advancements. 

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2769

On the contrary, lack of knowledge regarding the exact cause of psoriasis and its etiology, the high price of medications with their low efficacy and efficiency, side effects associated with symptomatic treatments, and lack of permanent and effective treatment are factors that may hamper the Psoriasis Drugs Market growth during the forecast period. 

Psoriasis Drugs Market Segmentation

The Market Research Future report offers a complete segmental analysis of the Psoriasis Drugs Market based on treatment type and drug class. 

By drug class, the Psoriasis treatment Market is segmented into vitamin D analogues, InterleU.K.in-inhibitors, and tumor necrosis factor inhibitors. The tumor necrosis factor inhibitors segment is again segmented into etanercept, infliximab, and adalimumab. The InterleU.K.in-inhibitors segment is again segmented into brodalumab, ixekizumab, SecU.K.inumab, and ustekinumab. The vitamin D analogues segment is again segmented into tacalcitol, calcipotriol, and calcitriol. 

By treatment, the Psoriasis Drugs Market is segmented into biologics, systematic, and topicals. The topicals segment is again segmented into topical steroids, topical non-steroids, and over the counter topicals. The systematic segment is again segmented into methotrexate, cyclosporine, and retinoid. The biologics segment is again segmented into T cell inhibitor, InterleU.K.in 17 (IL-17) inhibitor, InterleU.K.in 12 and 23 (IL-12/23) inhibitors, and tumor necrosis factor-alpha (TNF-a) inhibitors. 

Psoriasis Drugs Market Regional Analysis

By region, the Psoriasis Drugs Market report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific, the Middle East and Africa, and Latin America. Of these, North America will spearhead the market during the forecast period. Various factors are propelling the growth of the Psoriasis Drugs Market in the region, such as the growing awareness about psoriasis treatment, rising prevalence of psoriasis, presence of key manufacturers, and increasing health infrastructure. 

The Psoriasis Drugs Market in Europe will have the second-largest share during the forecast period. Various factors are propelling the growth of the Psoriasis Drugs Market in the region such as growing awareness about psoriasis, the launch of biosimilars (amzevita, elerzi), and increasing prevalence of psoriasis. 

The Psoriasis Drugs Market in the APAC region will grow at the fastest pace during the forecast period. Various factors are propelling the growth of the Psoriasis Drugs Market in the region such as growing geriatric population, large patient pool, improving medical facilities and healthcare infrastructure, increasing participation of key market players, increasing investments to develop new therapeutics to treat psoriasis, and increasing awareness. 

The Psoriasis Drugs Market in the MEA will have a small share during the forecast period for the low economic development in Africa. 

The Psoriasis Drugs Market in Latin America will have a favorable growth during the forecast period owing to the focus of manufacturers to create novel therapeutics and rise in the psoriasis patient pool. 

Psoriasis Drugs Market Key Players

Notable players profiled in the Psoriasis Drugs Market report include Eli Lilly and Company (US), Amgen (US), AbbVie (US), Merck and Co. Inc (US), Pfizer Inc (US), Johnson & Johnson (US), Celgene Corporation (US), AstraZeneca (UK), UCB (Belgium), and Novartis International AG (Switzerland).

Psoriasis Drugs Industry News

Daavlin, a renowned US-based phototherapy units’ manufacturer that utilizes therapeutic UV light to effectively and safely treat patients with eczema, vitiligo, and psoriasis have joined hands with HealthLens to give patients better access to receive a dermatology consultation as well as treatment right from their home. The patient just needs to book a consultation online, followed by uploading some pictures of the skin condition and brief health history, after which the information will get electronically encrypted and sent securely to the physician who will respond within 1-2 days. 

Browse More Healthcare Related Research Reports at:

Hybrid Operating Room Market Size Analysis, Trends | Application, 2023

CBD Oil Market by Type, Size, Share and Forecast – 2024

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Drugs Market Size Is Projected to Reach USD 13.1 Billion at a CAGR of 7.3% By 2025